for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boston Scientific Corporation

BSX

Latest Trade

42.80USD

Change

-0.60(-1.38%)

Volume

4,144,315

Today's Range

42.26

 - 

43.05

52 Week Range

32.99

 - 

46.28

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
43.40
Open
43.01
Volume
4,144,315
3M AVG Volume
137.08
Today's High
43.05
Today's Low
42.26
52 Week High
46.28
52 Week Low
32.99
Shares Out (MIL)
1,423.85
Market Cap (MIL)
61,795.20
Forward P/E
27.02
Dividend (Yield %)
--

Next Event

Q3 2021 Boston Scientific Corp Earnings Call

Latest Developments

More

Boston Scientific Announces Positive Late-Breaking Clinical Trial Data For The Ranger Drug-Coated Balloon

Minerva Surgical Inc Files For IPO Of Up To $100 Million

Boston Scientific Agrees To Acquire Devoro Medical

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by businesses such Interventional Cardiology, Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health, Neuromodulation and Specialty Pharmaceuticals. It operates in three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. MedSurg consists of Endoscopy and Urology and Pelvic Health businesses. Rhythm segment consists of Cardiac Rhythm Management, Electrophysiology and Neuromodulation businesses. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Industry

Medical Equipment & Supplies

Contact Info

300 BOSTON SCIENTIFIC WAY

MARLBOROUGH, MA

01752-1234

United States

+1.508.6834000

https://www.bostonscientific.com/

Executive Leadership

Michael F. Mahoney

Chairman of the Board, President, Chief Executive Officer

Daniel J. Brennan

Chief Financial Officer, Executive Vice President

Arthur C. Butcher

Executive Vice President and President, Asia Pacific

Joseph M. Fitzgerald

Executive Vice President, President, Interventional Cardiology

Edward F. Mackey

Executive Vice President - Global Operations

Key Stats

1.81 mean rating - 32 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

9.8K

2019

10.7K

2020

9.9K

2021(E)

12.0K
EPS (USD)

2018

1.470

2019

1.580

2020

0.960

2021(E)

1.606
Price To Earnings (TTM)
118.01
Price To Sales (TTM)
5.52
Price To Book (MRQ)
3.87
Price To Cash Flow (TTM)
37.96
Total Debt To Equity (MRQ)
57.14
LT Debt To Equity (MRQ)
55.49
Return on Investment (TTM)
2.13
Return on Equity (TTM)
1.88

Latest News

Latest News

Boston Scientific to buy Baylis Medical for $1.75 billion

Boston Scientific Corp said on Wednesday it would acquire Canada-based privately held medical device maker Baylis Medical Company Inc for $1.75 billion to expand its electrophysiology and heart product portfolios.

Boston Scientific to buy Baylis Medical for $1.75 billion

Medical device maker Boston Scientific Corp said on Wednesday it would acquire Baylis Medical Company Inc for $1.75 billion to expand its electrophysiology and heart product portfolios. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Vinay Dwivedi)

Boston Scientific on hook for $68K over sanctions in defibrillator case

Boston Scientific Corp, after being sanctioned for discovery violations in a whistleblower lawsuit over allegedly defective defibrillators, has been ordered to pay the plaintiff about $68,400 in fees and expenses related to the sanctions motion.

Boston Scientific prevails in defibrillator whistleblower case

Boston Scientific Corp has won summary judgment against a long-running whistleblower lawsuit accusing it of selling defective implantable cardiac defibrillators.

McDonald's hires new general counsel to head legal staff

McDonald's Corp on Monday said it hired Desiree Ralls-Morrison as general counsel and corporate secretary.

Boston Scientific in $189 million settlement with U.S. states over surgical mesh devices

Boston Scientific Corp agreed to pay $188.7 million to settle claims by most U.S. states that it deceptively marketed its surgical mesh devices to consumers.

BRIEF-Boston Scientific confirms multistate surgical mesh settlement

Boston scientific confirms multistate settlement over surgical mesh devices, and says it is not an admission of misconduct or liability

Boston Scientific reaches nearly $189 mln settlement over surgical mesh devices

Boston Scientific Corp agreed to pay nearly $189 million to settle claims by most U.S. states that it misled consumers about the safety and effectiveness of its surgical mesh devices.

NY sues Boston Scientific over surgical mesh devices

New York's attorney general on Tuesday filed a lawsuit accusing Boston Scientific Corp of concealing the risks of its surgical mesh devices.

Boston Scientific to buy surgical business of Lumenis for $1.07 billion

Boston Scientific Corp has agreed to buy the global surgical business of privately held Lumenis Ltd for $1.07 billion in cash, as the medical device maker looks to add an array of laser systems used in treating kidney stones to its portfolio.

Boston Scientific to buy surgical business of Lumenis for $1.07 billion

Medical device maker Boston Scientific Corp said on Wednesday it would buy the global surgical business of privately-held Lumenis Ltd for $1.07 billion in cash from Baring Private Equity Asia. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.)

BRIEF-Boston Scientific Says Many Countries Returned To Year-Over-Year Growth In Q3- Conf. Call

* SAYS MANY COUNTRIES RETURNED TO YEAR-OVER-YEAR GROWTH IN Q3- CONF. CALL

Boston Scientific reports loss as COVID-19 slams demand for medical devices

Boston Scientific Corp <BSX.N> swung to a loss in the third quarter from profit a year ago, as demand for its medical devices was hurt by the ongoing COVID-19 pandemic.

Boston Scientific reports loss as COVID-19 hits demand for medical devices

Boston Scientific Corp reported a third-quarter loss on Wednesday, hurt by lower demand for its medical devices.

Boston Scientific balks at fee request, saying sanctions motion didn't need 'army of lawyers'

Boston Scientific Corp, after being sanctioned for discovery violations in a whistleblower lawsuit over allegedly defective defibrillators and ordered to pay the plaintiff's legal fees for the sanctions motion, has accused the whistleblower of demanding "excessive" fees...

Boston Scientific sees improved July trends as elective surgery recovers

Medical device maker Boston Scientific Corp <BSX.N> on Wednesday posted a surprise adjusted quarterly profit and said demand for elective procedures picked up pace in July following an easing of coronavirus-driven restrictions.

BRIEF-Boston Scientific Exec Says July Trends Are Nicely Improving From June Levels- Conf. Call

* EXEC SAYS JULY TRENDS ARE NICELY IMPROVING FROM JUNE LEVELS- CONF. CALL

Boston Scientific swings to loss as medical device sales sink

Medical device maker Boston Scientific Corp reported a second-quarter loss on Wednesday, hurt by lower demand for specialty medical devices as patients continued to defer elective procedures during the COVID-19 pandemic.

BRIEF-Boston Scientific Corp - Kevin Ballinger Resigning To Take CEO Position At Co That Does Not Compete With Boston Scientific

* BOSTON SCIENTIFIC CORP - KEVIN BALLINGER RESIGNING TO TAKE CEO POSITION AT CO THAT DOES NOT COMPETE WITH BOSTON SCIENTIFIC Source text for Eikon: https://bit.ly/2XLd0hW Further company coverage:

BRIEF-Boston Scientific Receives Medicare Transitional Pass-Through Payment For The Exalt Model D Single-Use Duodenoscope

* BOSTON SCIENTIFIC RECEIVES MEDICARE TRANSITIONAL PASS-THROUGH PAYMENT FOR THE EXALT™ MODEL D SINGLE-USE DUODENOSCOPE Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up